ReviewJournal of anesthesia, analgesia and critical care2025
Diagnosis and management of invasive candidiasis in critically ill patients: SIAARTI multidisciplinary statement.
Review in Journal of anesthesia, analgesia and critical care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Critically ill patients in Intensive Care Units are at high risk of developing invasive candidiasis (IC). Delay in diagnosis and suboptimal management contribute to high mortality rates, highlighting the need for an appropriate and patient-tailored approach. The Italian Society of Anaesthesia, Analgesia, Resuscitation, and Intensive Care (SIAARTI) convened a multidisciplinary panel, involving intensivists, infectious disease specialists, microbiologists, and pharmacologists, to develop consensus-based statements on the diagnosis and management of IC in critically ill patients. The panel formulated 13 statements addressing key aspects of care, including identification of major risk factors for IC, the role of biomarkers to support therapeutic decision-making, and optimal selection of antifungal agents based on pharmacokinetic/pharmacodynamic (PK/PD) considerations and site-specific characteristics. The document also provides guidance on the use of therapeutic drug monitoring (TDM) to optimize antifungal efficacy. Special attention is given to infections in specific anatomical sites, such as the peritoneal cavity, central nervous system, eye, and biofilm-associated infections, where drug penetration and activity must be carefully considered. This multidisciplinary statement offers a practical framework aimed at improving clinical decision-making for the management of invasive candidiasis in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.